Development and Validation of an HPLC Method for the Purity Assay of BZM, the Precursor of Striatal Dopaminergic D2/D3 Receptor SPECT Imaging Agent [123I] IBZM (Iodobenzamide)

• Published in: Yàowu shi͡p︡in fenxi Vol. 16; no. 5; pp. 28 - 38
• Main Authors: 劉公典(Kung-Tien Liu), 楊漢興(Hang-Hsing Yang), 夏儀芝(Yi-Chih Hsia), 楊安水(An-Shoei Yang), 蘇昌勇(Chang-Yung Su), 林台生(Tai-Sheng Lin), 沈立漢(Lie-Hang Shen)
• Format: Journal Article
• Language: English; Chinese
• Published: 台灣 衛生福利部食品藥物管理署 01.10.2008
• Subjects: [123I]IBZM; BZM; Fragmentation pathway; IBZM; LC-ESI-MS/MS; MEDLINE; Method validation; MRM transition; MRM轉移; Purity assay; RP-HPLC; SCIE; Scopus; 方法確效; 碎裂路徑; 純度分析; MRM transition; Method validation; Purity assay; IBZM; LC-ESI-MS/MS; 方法確效; MRM轉移; RP-HPLC; BZM; 純度分析; 碎裂路徑; Fragmentation pathway; IBZM 123I IBZM; 123I IBZM

BZM是紋狀體多巴胺D2/D3受體(D2R) SPECT造影劑[123I]IBZM（碘苯醯胺，iodobenzamide）的前驅物與自由態螯合基。本研究利用逆相高效液相層析儀(RP-HPLC)，進行BZM純度分析方法開發與方法確效實驗。層析條件包括Zorbax eclipse XDB-C18管柱；10 mM醋酸銨緩衝溶液(pH 7.0)與乙腈混合梯度流洗液；0.5 mL/min流速與254 nm UV偵測波長。本方法在分析0.5-5.5μg樣品線性範圍時可得大於0.9997之相關係數。BZM主要不純物(impurity A, t(下标 R)-3.85 min)含量的最低偵測下限(LOD)與最低...